Literature DB >> 20533047

[Diabetic maculopathy and retinopathy. Functional and sociomedical significance].

J G Garweg1, A Wenzel.   

Abstract

OBJECTIVE: The incidence of diabetic microvascular complications is expected to increase by 20-50% in the coming years. Diabetic macular edema (DME) is already a leading cause of blindness in the working-age population in developed countries, and its impact is expected to increase dramatically.
METHODS: Recent literature on the epidemiology and impact of diabetic microangiopathy (maculopathy) on visual function was reviewed to provide a comprehensive overview of the functional and socioeconomic consequences of diabetic retinal microangiopathy and new therapeutic strategies.
RESULTS: The first changes indicating diabetic microangiopathy are detectable shortly after the development of hyperglycemia, and in the long term they induce severe organ damage. More resources are used for this condition's treatment than for the treatment of hyperglycemia, corresponding to an enormous sociomedical burden of disease. Early detection of increased retinal vascular permeability may help control treatment effects. The control of recognized risk factors for the development and progression of DME, namely hyperglycemia and hyperlipidemia, as well as of hypertension has remained the cornerstone of therapy and serves as the basis for preserving visual function.
CONCLUSIONS: Modern treatment options, begun early, may result in a remarkably delayed occurrence of irreversible diabetic microvascular pathologies, particularly diabetic retinopathy and maculopathy. Ophthalmological screening nowadays aims at earlier recognition of at-risk individuals to optimize the therapeutic strategy--that is, before visual impairment is imminent. Close interdisciplinary medical cooperation and implementation of new therapeutic options may provide the foundation for success in terms of maintaining visual function.

Entities:  

Mesh:

Year:  2010        PMID: 20533047     DOI: 10.1007/s00347-010-2176-x

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  142 in total

Review 1.  Update on treatments for diabetic macular edema.

Authors:  Samantha Fraser-Bell; Andrew Kaines; Phillip G Hykin
Journal:  Curr Opin Ophthalmol       Date:  2008-05       Impact factor: 3.761

Review 2.  Vascular endothelial growth factors and angiogenesis in eye disease.

Authors:  A N Witmer; G F J M Vrensen; C J F Van Noorden; R O Schlingemann
Journal:  Prog Retin Eye Res       Date:  2003-01       Impact factor: 21.198

3.  Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

Authors:  A C Keech; P Mitchell; P A Summanen; J O'Day; T M E Davis; M S Moffitt; M-R Taskinen; R J Simes; D Tse; E Williamson; A Merrifield; L T Laatikainen; M C d'Emden; D C Crimet; R L O'Connell; P G Colman
Journal:  Lancet       Date:  2007-11-07       Impact factor: 79.321

4.  Galactose-induced retinal capillary basement membrane thickening: prevention by Sorbinil.

Authors:  R N Frank; R J Keirn; A Kennedy; K W Frank
Journal:  Invest Ophthalmol Vis Sci       Date:  1983-11       Impact factor: 4.799

5.  Major diabetes-related vascular events do not improve glycaemic control in a population-based cohort of type 1 diabetic individuals.

Authors:  Trine Maria Mejnert Jørgensen; Jakob Grauslund; Anne Katrin Sjølie; Anders Green; Lars Melholt Rasmussen; Mads Nybo
Journal:  Scand J Clin Lab Invest       Date:  2009       Impact factor: 1.713

6.  Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study.

Authors:  Quan Dong Nguyen; Syed Mahmood Shah; Jeffery S Heier; Diana V Do; Jennifer Lim; David Boyer; Prema Abraham; Peter A Campochiaro
Journal:  Ophthalmology       Date:  2009-08-22       Impact factor: 12.079

7.  Risk factors for mortality and ischemic heart disease in patients with long-term type 1 diabetes.

Authors:  Jakob Grauslund; Trine M M Jørgensen; Mads Nybo; Anders Green; Lars M Rasmussen; Anne Katrin Sjølie
Journal:  J Diabetes Complications       Date:  2009-07-03       Impact factor: 2.852

8.  Captopril inhibits capillary degeneration in the early stages of diabetic retinopathy.

Authors:  Jin-Zhong Zhang; Xia Xi; Ling Gao; Timothy S Kern
Journal:  Curr Eye Res       Date:  2007-10       Impact factor: 2.424

9.  Impact of ecology on development of NIDDM.

Authors:  D A R K Dayaratne
Journal:  Med Hypotheses       Date:  2010-01-12       Impact factor: 1.538

10.  Diabetes prevalence in England, 2001--estimates from an epidemiological model.

Authors:  N G Forouhi; D Merrick; E Goyder; B A Ferguson; J Abbas; K Lachowycz; S H Wild
Journal:  Diabet Med       Date:  2006-02       Impact factor: 4.359

View more
  2 in total

Review 1.  Diabetic retinopathy - ocular complications of diabetes mellitus.

Authors:  Martin M Nentwich; Michael W Ulbig
Journal:  World J Diabetes       Date:  2015-04-15

2.  A systematic review and meta-analysis to compare the efficacy of conbercept with ranibizumab in patients with macular edema secondary to retinal vein occlusion.

Authors:  Weishai Liu; Yanjie Li; Rongxia Cao; Zichao Bai; Weiqin Liu
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.